About our department
Prof. dr. P.H.M. van der Kuy
Head of department of Hospital Pharmacy
Prof. K.M. Allegaert
Professor at KU Leuven, Senior clinical researcher
Prof. dr. B.C.P. Koch
Professor at Erasmus MC, group of Clinical Pharmacometrics
Dr. N.G.M. Hunfeld
Dr. S.L.W. Koolen
Dr. R.W.F. van Leeuwen
Dr. F. van Rosse
Dr. I.H. van der Sijs
Dr. J. Versmissen
Dr. L.E. Visser
Dr. B.C.M. de Winter
Dr. R. Bouamar
Dr. M.R.B.S. Crombag
Dr. R.B. Flint
Dr. E.J. Ruijgrok
Dr. R.J. Zaal
S.J. van Tilburg
Targets for the future
Our targets for the future
- Research line 1: Medication Optimization and Safety;
- Research line 2: Clinical Pharmacometrics;
- Research line 3: Drug Innovation.
We will focus on several developments that can influence and increase our research possibilities:
- The Erasmus MC will build a new ATMP facility. The involvement of a pharmacist is crucial here, in terms of advice and oversight regarding preparation, handling and storage activities for ATMPs. Several groups within the Erasmus MC perform cutting-edge clinical research with ATMPs, which offers the potential for the strong involvement of a dedicated ATMP pharmacist. This research line is still in development, but it might lead to two separate lines in the future. The first line will focus on oncolytic viruses in cooperation with the Department of Virology. The second line might cooperate with the Department of Haematology to focus on the use – and our own production of – T-cells.
Radiopharmacy is also fast becoming a new research opportunity. The Erasmus MC has a track record in this field with the development of Lutetium for NET cancer. The Department of Radiology and Nuclear Medicine is seeking cooperation with our department in this area, but successful further development of this research line will take another three to five years.
- The Department of Pharmacy is committed to increasing the quantity and quality of our scientific output, and we aim for the first quartile of MNCS scores within the Erasmus MC. As always, our research needs to be directed at solving clinically-relevant issues that promote patient safety and patient outcome.
Hassna Akhloufi. Antibiotic Stewardship – Clinical decision support systems to improve antibiotic use in hospitals. (18-06-2021)
Florine Berger. Drug induced QTc-prolongation. Towards a better understanding of potential risks.(28-04-2021)
Sanne Kloosterboer. What's in a Drop of Blood? Towards individualized treatment with antipsychotic drugs in children and adolescents. (20-01-2021)
Koen Hussaarts. Drug-drug interactions in patients treated with tyrosine kinase inhibitors. (18-11-2020)
Femke de Velde. Dosing Optimization of Beta-Lactam Antibiotics using Parametric and Nonparametric Population Pharmacokinetic Models. (14-10-2020)
Suzanne Schol-Gelok. Influence of (co-)medication on haemostatic biomarkers. (23-09-2020)
Louise Andrews. Model Based Dosing Of Tacrolimus After Renal Transplantation. (11-12-2019)
Rixt Wijma. Pharmacokinetic profiling of fosfomycin and nitrofurantoin to optimize the treatment of uncomplicated urinary tract infections. (10-12-2019)
Albert Dreijer. Antithrombotic stewardship. (18-10-2019)
Liesbeth Bosma. Medication Safety in Critically Ill Patients. (6-9-2019)
Annette van der Vossen. Paediatric Formulistions Pharmaceutical Development and Clinical Evaluation. (25-11-2018)
Robert Flint. Evidence-based pharmacotherapy in preterm infants. (14-11-2018)
Linda Franken. Drugs dosing at the end of life. (7-2-2018)
Hendrika Cornelia Aartje Maria Hazendonk, Pharmacokinetic-guided dosing of clotting factor concentrates in bleeding disorders. (302017)
Maja Matic. Personalized pain therapy. (27-6-2017)
For the publications concerning our research line Medication Optimization and Safety, click here.
For the publications concerning our research line Clinical Pharmacometrics, click here.
For the publications concerning our research line Drug Innovation, click here.
Our 2021 Key Publications
Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial
Marith I Francke, Louise M Andrews, Hoang Lan Le, Jacqueline van de Wetering, Marian C Clahsen-van Groningen, Teun van Gelder, Ron H N van Schaik, Bronno van der Holt, Brenda C M de Winter, Dennis A Hesselink Clin Pharmacol Ther. 2021 Jul;110(1):169-178. doi: 10.1002/cpt.2163. Epub 2021 Feb 23.
Our 2020 Key Publications
- Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT)
Alan Abdulla, Annemieke Dijkstra, Nicole G. M. Hunfeld, Henrik Endeman, Soma Bahmany, Tim M. J. Ewoldt, Anouk E. Muller, Teun van Gelder, Diederik Gommers and Birgit C. P. Koch
Critical Care (2020) 24:558 https://doi.org/10.1186/s13054-020-03272-z
- COvid MEdicaTion (COMET) study: protocol for a cohort study
Roos S G Sablerolles, Freija E F Hogenhuis, Melvin Lafeber, Bob P A van de Loo, Sander D Borgsteede, Eric Boersma, Jorie Versmissen, Hugo M van der Kuy, COMET Research team
Eur J Hosp Pharm. 2020 Jul;27(4):191-193.
- Precision Dosing of Doxapram in Preterm Infants Using Continuous Pharmacodynamic Data and Model-Based Pharmacokinetics: An Illustrative Case Series.
Poppe JA, van Weteringen W, Sebek LLG, Knibbe CAJ, Reiss IKM, Simons SHP, Flint RB
Front Pharmacol. 2020 May 12;11:665. doi: 10.3389/fphar.2020.00665. eCollection 2020.PMID: 32477133
- Clinical implications of food-drug interactions with small-molecule kinase inhibitors.
Veerman GDM Hussaarts KGAM, Jansman FGA, Koolen SLW, van Leeuwen RWF, Mathijssen RHJ
Lancet Oncol. 2020 May;21(5
- Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs
John N Van den Anker, Susan McCune, Pieter Annaert, Gerri R Baer, Yeruk Mulugeta, Ramy Abdelrahman, Kunyi Wu, Kevin M Krudys, Jeffrey Fisher, William Slikker, Connie Chen, Gilbert J Burckart, Karel Allegaert
Pharmaceutics. 2020 Jul 20;12(7):685. doi: 10.3390/pharmaceutics12070685.
- Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder
Sanne Maartje Kloosterboer, Brenda C M de Winter, Catrien G Reichart, Mirjam E J Kouijzer, Matthias M J de Kroon, Emma van Daalen, Wietske A Ester, Rob Rieken, Gwen C Dieleman, Daphne van Altena, Beatrijs Bartelds, Ron H N van Schaik, Kazem Nasserinejad, Manon H J Hillegers, Teun van Gelder, Bram Dierckx, Birgit C P Koch
Br J Clin Pharmacol. 2020 Jul 9. doi: 10.1111/bcp.14465. Online ahead of print.
- Physicians' acceptance of pharmacists' interventions in daily hospital practice.
Zaal, R.J., den Haak, E.W., Andrinopoulou, E.R., van Gelder, T., Vulto, A.G., van den Bemt, P.M.L.A.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 42 (1), 141-149.
- Comparison of two algorithms to support medication surveillance for drug-drug interactions between QTc-prolonging drugs
Florine A Berger, Heleen van der Sijs, T. van Gelder, Aaf F M Kuijper, Patricia M L A van den Bemt, Matthijs L Becker
Int J Med Inform. 2020 Nov 4;145:104329. doi: 10.1016/j.ijmedinf.2020.104329.
- Veilig voorschrijven bij levercirrose: 5 misvattingen
Rianne A. Weersink, Joost P.H. Drenth, Frank ter Borg, Midas B. Mulder, Katja Taxis and Sander D. Borgsteede
Nederlands Tijdschrift voor geneeskunde
- Does a Dose Calculator as an Add‑On to a Web‑Based Paediatric Formulary Reduce Calculation Errors in Paediatric Dosing? A Non‑Randomized Controlled Study
Tjitske M. van der Zanden, Matthijs de Hoog, Jonathan D. Windster, Joost van Rosmalen, I. Heleen van der Sijs and Saskia N. de Wildt
Paediatr Drugs. 2020; 22(2): 229–239.
- Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients
Marith I Francke, Dennis A Hesselink, Yi Li , Birgit C P Koch, Lucia E A de Wit, Ron H N van Schaik, Lin Yang, Carla C Baan, Teun van Gelder, Brenda C M de Winter
Br J Clin Pharmacol. 2020 Oct 6. doi: 10.1111/bcp.14585. Online ahead of print.
- Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
Tim Preijers, Lisette M. Schütte, Marieke J. H. A. Kruip, Marjon H. Cnossen, Frank W. G. Leebeek, Reinier M. van Hest & Ron A. A. Mathôt
Clinical Pharmacokinetics (2020)
- Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors
Florence Atrafi, Ruben A.G. van Eerden, Marte A.M van Hylckama Vlieg, Esther Oomen-de Hoop, Peter de Bruijn, Martijn P. Lolkema, Adriaan Moelker, Cristianne J. Rijcken, Rob Hanssen, Alex Sparreboom, Ferry A.L.M. Eskens, Ron H.J. Mathijssen and Stijn L.W. Koolen
Clinical cancer research
- Clinical Applicability of Monitoring Antihypertensive Drug Levels in Blood
Peeters LEJ, Feyz L, Boersma E, Daemen J, van Gelder T, Koch BCP, Versmissen J.
Hypertension. 2020 Jul;76(1):80-86. doi: 10.1161/HYPERTENSIONAHA.120.15038. Epub 2020 May 18.PMID: 32418497
- Letter to the editor: Comments on 'A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation'.
Diekstra MHM, Malmberg R, Sleijfer S, van Leeuwen RWF
Eur J Cancer. 2020 Aug 24;138:54-56. doi: 10.1016/j.ejca.2020.07.014. Online ahead of print.
The Department of Pharmacy has research facilities for its research and to support research from other departments:
- KGO (klinisch geneesmiddel onderzoek) supports all drug research in our hospital with extensive knowledge about GMP and GCP.
- The Department of Pharmacy's laboratory is one of the largest TDM and toxicology laboratories in the Netherlands. It is ISO15189-accredited and we analyse over 15,000 research samples each years for the other departments (as well as 60,000 diagnostic samples each year).
- CPO consultants: three staff members are official CPO consultants.
- The following collaborations with research facilities also exist:
- Advanced Therapy Medicinal Products (ATMP): An expert centre for the production of advanced therapy medicinal products. The Department of Pharmacy will play a central role in building and exploiting the new ATMP facility.
- ERGO: A prospective cohort study on the risk factors and determinants of chronic diseases in middle-aged and elderly persons. Over the years, several pharmacists have obtained their PhDs in studies within ERGO.
- Genomics: An expertise Center for Genomics Research. Collaborations for research in pharmacogenetics have been very succesful (Pharmacogenetics Core Lab - Clinical Chemistry).
- The Department of Cell Biology's Mass Spectrometry Facility: Collaboration involves equipment for the analysis of new compounds and with regards to buying equipment.
The department of Pharmacy has many collaborations, often based on our role in the hospital. Research and the clinical part of the department are closely linked, and most research comes from clinical practice and questions about hospital patients.
Our department's front office contains clinical hospital pharmacists who work in the wards and consult with clinicians, nurses and other health care providers. Each ward has a dedicated team of pharmacists and pharmacy technicians.
All of our pharmacists also work in the department's back office, tightly linking the front office and the back office to translate clinical consultations to logistics, manufacturing, quality and laboratory analysis. We can also translate research-related subjects to our back office, as we help execute drug research (KGO, clinical drug research) and laboratory analysis. This infrastructure also connects our own research lines to all other parts.
Our research lines are most closely connected with the Departments of Internal Medicine, Virology, Microbiology, Oncology, Immunology and Psychiatry. All of these collaborations are strategic, based on expertise in certain areas, and they help to increase output, visibility and patient participation in research.
Our partnerships with Barcelona and Louvain reflect longstanding collaborations in research focused on the treatment of kidney transplant patients. Together with Rotterdam, these centres from the largest transplant centres in Europe, and incorporate many patients in clinical studies. We also have a ten year collaboration with Chengdu (China). Over the years seven research fellows from Chengdu to the Erasmus MC (and vice versa) were supported by NWO-NCSF joint program grants. The value of this collaboration is mostly in the development of clinical research in China.
We also collaborate with the Rennes University Hospital (France), and Master students from Rennes have a research residency in our department which has led to several joint publications.
In October 2019, Dr. Birgit Koch has started a visiting professorship in Indonesia at the University of Yogyakarta, where she teaches Therapeutic Drug Monitoring, Model-based Dosing and Analytical Methods. She also collaborates internationally within EPASG (the ESCMID PK/PD of Anti-infectives Study Group), as well as with researchers in Brisbane (Australia), and investigators in Vienna (Austria) and Geneva (Switzerland) on pharmacokinetic research. Within the European Union, she is involved in several EU projects such as COMBACTE, AIDA and GNA Now.
One staff member collaborates with the group of Mats Karlsson at Upssala University (Sweden) and just started a collaboration with the University of Chansha in China.
Furthermore, we also collaborate with:
- prof. dr. David Bates, Prof. Dan Malone and Dr. Richard Boyce in the area of medication safety;
- dr. John Devlin in the area of delirium research;
- prof. dr. Mike Scott (Antrim, North Ireland) and prof. dr. Bert Aertgeest (Leuven, Belgium) in the area of clinical decision support.
We cooperate with more than 12 countries through an European grant (I-live). There is also intense cooperation with Switzerland and Sweden in the area of medication optimisation in the last phase of life.
Overview of our international collaborations
- University of Yogyakarta: dr. Thobari
- University of Leuven: Prof. dr. Spriet and Prof. dr. Allegeart
- University of Gent: dr. de Cock
- University of Cincinnati Childrens: Prof. dr. Vinks
- University of Mount Sinai: Prof. dr. Bergink
- University of Vienna: Prof. dr. Zeitlinger
- University Rennes: dr. Lemaitre
- University Brisbane: Prof. dr. Roberts
- University of Sydney: Prof. dr. Marriott and Prof. dr. Alffenaer
Extending our existing collaborations
Model-based precision dosing applies to a wide range of drugs and that's why our collaborations are elaborately.
- Pediatric intensive care: Prof. dr. de Hoog
- Infectious diseases: Prof. dr. Verbon, dr. Muller and Prof. dr. van Rossum
- Child psychiatry: Prof. dr. Hillegers and dr. Dierckx
- Neonatology: Prof. dr. Reiss and dr. Simons
- Gynaecology: Prof. dr Steegers and dr. Schoemakers
- Pharmacology: Prof. dr. Danser and dr. Maassen-van den Brink
- Intensive care: Prof. dr. Gommers and dr. Endeman
- Public Health: dr. Polinder
- Internal Medicine: dr. Versmissen
- Neurology-immunology: Prof. dr Jacobs and Prof. dr. van Doorn
- Medical Oncology: Prof. dr. Mathijssen, Prof. dr. Sleijfer and dr. S Koolen
- Clinical Chemistry: Prof. dr. van Schaik
- Radboud UMC: dr. Bruggemann, dr. ter Heine, dr. van Erp and Prof. dr. De Wildt
- Amsterdam UMC: dr. van Hest
- LUMC: Prof. dr. van Gelder
For general vacancies, click here.